|Milatuzumab-Doxorubicin Antibody-Drug Conjugate (Code C91086)|
|Terms & Properties|
Preferred Name: Milatuzumab-Doxorubicin Antibody-Drug Conjugate
Definition: An immunoconjugate consisting of milatuzumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatuzumab moiety of this ADC selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells.
NCI-GLOSS Definition: A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. IMMU-110 is a type of monoclonal antibody.
Display Name: Milatuzumab-Doxorubicin Antibody-Drug Conjugate
Label: Milatuzumab-Doxorubicin Antibody-Drug Conjugate
NCI Metathesaurus Link: C1615035 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
|Milatuzumab-Doxorubicin Antibody-Drug Conjugate|
External Source Codes:
|PDQ Closed Trial Search ID||671813|
|PDQ Open Trial Search ID||671813 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|